N/A
N=250
Communication and Activation in Pain to Enhance Relationships and Treat Pain With Equity
Pain
Bottom Line
View on ClinicalTrials.gov: NCT03562793 ↗Enrolled (actual)
250
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Patient Activation — 60.39; 57.58 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Activation |
61.56; 58.56 | — |
| PRIMARY Patient Activation |
61.56; 58.56 | — |
| PRIMARY Patient Activation |
61.56; 58.56 | — |
| PRIMARY Patient Activation |
61.56; 58.56 | — |
| SECONDARY Communication Self-Efficacy (Perceived Efficacy in Patient-Physician Interactions--PEPPI) |
39.46; 37.98 | — |
| SECONDARY Pain Intensity and Interference (Brief Pain Inventory) |
5.46; 5.02 | — |
| SECONDARY Depression (PHQ8) |
8.87; 8.87 | — |
| SECONDARY Anxiety |
7.11; 7.14 | — |
| SECONDARY Pain Coping |
14.42; 13.91 | — |
| SECONDARY Communication Self-Efficacy (Perceived Efficacy in Patient-Physician Interactions--PEPPI) |
39.46; 37.98 | — |
| SECONDARY Communication Self-Efficacy (Perceived Efficacy in Patient-Physician Interactions--PEPPI) |
39.46; 37.98 | — |
| SECONDARY Communication Self-Efficacy (Perceived Efficacy in Patient-Physician Interactions--PEPPI) |
39.46; 37.98 | — |
| SECONDARY Pain Intensity and Interference (Brief Pain Inventory) |
5.46; 5.02 | — |
| SECONDARY Pain Intensity and Interference (Brief Pain Inventory) |
5.46; 5.02 | — |
| SECONDARY Pain Intensity and Interference (Brief Pain Inventory) |
5.46; 5.02 | — |
| SECONDARY Depression (PHQ8) |
8.87; 8.87 | — |
| SECONDARY Depression (PHQ8) |
8.87; 8.87 | — |
| SECONDARY Depression (PHQ8) |
8.87; 8.87 | — |
| SECONDARY Anxiety |
7.11; 7.14 | — |
| SECONDARY Anxiety |
7.11; 7.14 | — |
| SECONDARY Anxiety |
7.11; 7.14 | — |
Summary
Chronic pain affects approximately 100 million Americans and 40-70% of Veterans, and amounts to over $600 billion/year in direct medical costs and lost worker productivity. Racial disparities in pain care are well-documented, within and outside VA. Minorities are more likely to be undertreated for pain, are subjected to more urine drug tests, and are referred for substance abuse evaluation more frequently than Whites. Minority patients also exhibit lower levels of engagement and active involvement in their healthcare, which leads to poorer communication with providers and poorer outcomes. COOPERATE is a randomized controlled trial testing an intervention to improve minority Veterans' active participation in their pain care by focusing on 2 essential skill sets: 1) goal-setting and prioritization, and 2) communication skills.
Eligibility Criteria
Inclusion Criteria
- Black or African American Veteran
- Have musculoskeletal pain in the low back, cervical spine, or extremities (hip, knee, shoulder) for 3 months
Exclusion Criteria
Patients will be excluded if electronic medical records indicate:
- a psychotic disorder diagnosis
- current substance use disorder
- severe medical conditions precluding participation (e.g., NY Heart Association Class III or IV heart failure), or if the eligibility
Data sourced from ClinicalTrials.gov (NCT03562793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.